机构:
Med Coll Wisconsin, Dept Pathol & Lab Med, Milwaukee, WI USA
Med Coll Wisconsin, Neurosci Res Ctr, Milwaukee, WI USAMed Coll Wisconsin, Dept Pathol & Lab Med, Milwaukee, WI USA
Lawlor, Michael W.
[1
,2
]
Dowling, James J.
论文数: 0引用数: 0
h-index: 0
机构:
Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada
Hosp Sick Children, Program Genet & Genome Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada
Univ Toronto, Dept Paediat, Toronto, ON, Canada
Univ Toronto, Dept Mol Genet, Toronto, ON, CanadaMed Coll Wisconsin, Dept Pathol & Lab Med, Milwaukee, WI USA
Dowling, James J.
[3
,4
,5
,6
]
机构:
[1] Med Coll Wisconsin, Dept Pathol & Lab Med, Milwaukee, WI USA
[2] Med Coll Wisconsin, Neurosci Res Ctr, Milwaukee, WI USA
[3] Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada
[4] Hosp Sick Children, Program Genet & Genome Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada
[5] Univ Toronto, Dept Paediat, Toronto, ON, Canada
[6] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada
X-linked myotubular myopathy (XLMTM) is a severe congenital muscle disease caused by mutation in the MTM1 gene. MTM1 encodes myotubularin (MTM1), an endosomal phosphatase that acts to dephosphorylate key second messenger lipids PI3P and PI3,5P2. XLMTM is clinically characterized by profound muscle weakness and associated with multiple disabilities (including ventilator and wheelchair dependence) and early death in most affected individuals. The disease is classically defined by characteristic changes observed on muscle biopsy, including centrally located nuclei, myofiber hypotrophy, and organelle disorganization. In this review, we highlight the clinical and pathologic features of the disease, present concepts related to disease pathomechanisms, and present recent advances in therapy development. (C) 2021 The Authors. Published by Elsevier B.V.